| Cat. No. |
Product Name & Pharmacological Action |
| 2201 | PNU 22394 hydrochloride |
| 5-HT2C agonist and 5-HT2A/2B partial agonist |
| 2202 | Zatebradine hydrochloride |
| Bradycardic agent; blocks If pacemaker current |
| 2203 | PALDA |
| Endogenous lipid; potentiates effects of endovanilloids at TRPV1 receptors |
| 2204 | STEARDA |
| Endogenous lipid, active in vivo. Enhances effects of endovanilloids at TRPV1 receptors |
| 2206 | 2-Palmitoylglycerol |
| Endogenous lipid; enhances activity of 2-AG |
| 2207 | PDZ1 Domain inhibitor peptide |
| Disrupts interaction between GluR6 and PSD-95 PDZ1 domain |
| 2208 | LY 255283 |
| Selective, competitive BLT2 receptor antagonist |
| 2213 | N20C hydrochloride |
| Non-competitive NMDA receptor open-channel blocker |
| 2214 | ABT 724 trihydrochloride |
| Potent, selective D4 partial agonist; proerectile |
| 2215 | Urotensin II-related peptide |
| Endogenous urotensin II receptor agonist |
| 2216 | des-His1-[Glu9]-Glucagon (1-29) amide |
| Glucagon receptor antagonist |
| 2217 | HIP-A |
| Potent, non-competitive EAAT inhibitor |
| 2218 | HIP-B |
| Potent, non-competitive EAAT inhibitor |
| 2221 | Rac1 Inhibitor W56 |
| Selective inhibitor of Rac1-GEF interaction |
| 2222 | Rac1 Inhibitor F56, control peptide |
| Control peptide version of Rac1 Inhibitor W56 (Cat. No. 2221) |
| 2226 | Flutax 1 |
| Fluorescent taxol derivative |
| 2227 | CI 976 |
| Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor |
| 2228 | Leflunomide |
| Immunosuppressant |
| 2229 | GW 0742 |
| Highly selective, potent PPARδ agonist |
| 2231 | Anti-CB2 |
| Antibody recognising CB2 receptors |
| 2233 | Anti-TRPV1 |
| Antibody recognising TRPV1 receptors |
| 2235 | L803 |
| Substrate-competitive inhibitor of GSK-3 |
| 2236 | TCS 183 |
| Fragment 1-13 of GSK-3β sequence |
| 2237 | BRL 50481 |
| Selective PDE7 inhibitor |
| 2238 | GW 441756 |
| Potent, selective TrkA inhibitor |
| 2239 | GW 583340 dihydrochloride |
| Potent dual EGFR/ErbB2 inhibitor; orally active |
| 2241 | DMAB-anabaseine dihydrochloride |
| Partial agonist at α7-containing receptors and antagonist at α4β2 neuronal nicotinic receptors |
| 2242 | Octopamine hydrochloride |
| Invertebrate biogenic amine: activates β3 adrenoceptors |
| 2243 | MEK Inhibitor TocrisetTM |
| Selection of 3 MEK inhibitors (Cat. Nos. 1213, 1969 and 1144) |
| 2244 | p38 MAPK Inhibitor TocrisetTM |
| Selection of 3 p38 MAPK inhibitors (Cat. Nos. 1264, 1202 and 1962) |
| 2250 | SL 0101-1 |
| Selective p90 ribosomal S6 kinase (RSK) inhibitor |
| 2251 | Cisplatin |
| Potent proapoptotic anticancer agent; activates caspase-3 |
| 2252 | Doxorubicin hydrochloride |
| Antitumor antibiotic agent. Inhibits DNA topoisomerase II |
| 2253 | Go 6976 |
| Potent protein kinase C inhibitor; selective for α and β isozymes |
| 2254 | ACDPP hydrochloride |
| Selective mGlu5 receptor antagonist |
| 2255 | CGS 9343B |
| Calmodulin antagonist |
| 2257 | GIP (1-39) |
| Highly potent insulinotropic peptide |
| 2258 | GLP-2 (human) |
| Endogenous hormone; displays intestinotrophic activity |
| 2259 | GLP-2 (rat) |
| Endogenous hormone; displays intestinotrophic activity |
| 2260 | [Des-octanoyl]-Ghrelin (human) |
| Major circulating form of ghrelin; devoid of activity at GHS receptor but is active in vivo |
| 2261 | L-692,585 |
| Potent, non-peptide GHS receptor agonist |
| 2262 | WRW4 |
| Selective FPRL1 antagonist |
| 2264 | Motilin (human, porcine) |
| Endogenous peptide regulator of gastrointestinal motility |
| 2265 | Lyn peptide inhibitor |
| Inhibits Lyn-dependent activities of IL-5 receptor; cell-permeable |
| 2266 | DY131 |
| Agonist selective for estrogen-related receptors ERRβ and ERRγ |
| 2267 | Lactacystin |
| Cell-permeable, potent and selective proteasome inhibitor |
| 2268 | NNC 55-0396 dihydrochloride |
| Highly selective T-type Ca2+ channel inhibitor |
| 2270 | SCH 58261 |
| Potent, highly selective A2A antagonist |
| 2271 | GW 6471 |
| PPARα antagonist |
| 2272 | Ro 08-2750 |
| Inhibitor of NGF-induced apoptosis |
| 2273 | PMPA (NMDA antagonist) |
| Competitive NMDA antagonist |
| 2274 | PPPA |
| Competitive NR2A antagonist |
| 2275 | TBB |
| Selective cell-permeable CK2 inhibitor |
| 2276 | FPL 55712 |
| Leukotriene receptor antagonist |
| 2280 | Raloxifene hydrochloride |
| Selective estrogen receptor modulator (SERM) |
| 2281 | 2'-MeCCPA |
| Very selective and potent A1 receptor agonist |
| 2282 | Moxonidine hydrochloride |
| I1 receptor and α2-adrenoceptor agonist (I1 > α2) |
| 2284 | SEW 2871 |
| Cell-permeable, selective S1P1 receptor agonist |
| 2285 | Go 6983 |
| Broad spectrum PKC inhibitor |
| 2287 | K-252c |
| Protein kinase C inhibitor |
| 2288 | O-1918 |
| Silent antagonist for putative abnormal-CBD receptor |
| 2289 | Lamotrigine isethionate |
| Water-soluble salt of Cat. No. 1611 |
| 2290 | Sibutramine hydrochloride |
| 5-HT and noradrenaline re-uptake inhibitor (SNRI) |
| 2291 | 1,2,3,4,5,6-Hexabromocyclohexane |
| Inhibits Jak2 autophosphorylation |
| 2292 | AQ-RA 741 |
| Selective, high affinity M2 antagonist |
| 2293 | Zebularine |
| DNA methyltransferase and cytidine deaminase inhibitor |
| 2294 | Cordycepin |
| Anticancer and antifungal agent |
| 2295 | (±)-Cloprostenol sodium salt |
| Water-soluble PGF2α analogue and potent FP receptor agonist |
| 2296 | Prostaglandin E2 |
| Major endogenous prostanoid |
| 2297 | Misoprostol |
| Cytoprotective PGE1 analogue |
| 2299 | SCH 39166 hydrobromide |
| High affinity D1/D5 receptor antagonist |
| |
